Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation Therapy
GI pathology identified in our elderly patient population was commonly identified on pretreatment CS. Screening CS may optimize bowel health for patients heading into radiation therapy. Toxicity and QoL for patients with GI pathologies identified on pretreatment CS do not preclude the delivery of prostate SBRT. We advocate for pretreatment CS in patients eligible prior to SBRT.
Authors
- Beatriz Vizcaíno
- Sam Serouya
- J.A. Haas
- Scot A. Niglio (ORCID: https://orcid.org/0000-0002-1421-1533)
- Vianca F. Santos
- S.R. Blacksburg
- Christopher Mendez (ORCID: https://orcid.org/0000-0001-5439-3901)
- William C. Huang (ORCID: https://orcid.org/0000-0001-5261-0650)
- Samir S. Taneja (ORCID: https://orcid.org/0000-0003-0887-8259)
- Jonathan W. Lischalk (ORCID: https://orcid.org/0000-0002-3714-7757)
- Moses Tam (ORCID: https://orcid.org/0000-0002-2011-4211)
- K. Maloney-Lutz
- Michael J. Zeléfsky (ORCID: https://orcid.org/0000-0002-6090-6424)
- Astrid Sánchez (ORCID: https://orcid.org/0000-0002-5190-8487)
- Todd C. Carpenter (ORCID: https://orcid.org/0000-0002-9855-0021)
Institutions
- Brooklyn Hospital Center (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- NYU Langone Health (US)
- Accuray (United States) (US)
- New York University (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1016/j.adro.2025.101747
- Primary Topic
- Advanced Radiotherapy Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00